Scrip Intelligence: Early-Stage Funding Slips Again (VC Roundup)

Back Bay Life Science Advisors CEO Jonathan Gertler was interviewed by Scrip Pharma Intelligence for, “VC Roundup: Early-Stage Funding Slips Again In Third Quarter, Plus 15 New Financings”.  The article focused on the continued decline of early-stage venture capital funding as corporate VC dollars and other sources of cash are emerging to fund startups.

“There are not as many venture firms as there used to be that are willing to invest in small Series A rounds for startups led by new entrepreneurs or academics. That’s why big pharma and large biotech companies have become bigger backers of innovation at that level, either through corporate VC investments, partnerships with university labs or incubators that support nascent therapeutics developers . . .”

“From the venture capital side of it, the amount of VC groups focusing on technology at the early stage decreased substantially. It is hard to make money if you’re focused at the seed stage” “There are a lot more ways to form companies than the traditional conveyor belt - People need to think hard about strategy and structure when putting together new entities or funding an idea.”

For Scrip Intelligence subscribers, the full article can be read here.